Favuzza P, Dans MG, Su W, Thompson JK, Hodder AN, Ngo A, Penington JS, Marapana DS, Dziekan JM, Papenfuss AT, de Lera Ruiz M, Coyle R, Lee MCS, McCauley JA, Lowes K, Olsen DB, Sleebs BE, Cowman AF. Dual plasmepsin IX and X inhibitors are refractory to development of resistance. PLOS Pathogens. 2026;22(9):10.1371/journal.ppat.1014068
Schenk P, Devine SM, Cobbold SA, Geoghegan ND, Kyran EL, Ang C-S, Alexandrovics JA, Calleja DJ, Multari DH, Vaibhav V, Lu BGC, Klemm TA, Dagley LF, Lowes KN, Williamson NA, Eichhorn PJA, Ng AP, Feltham R, Komander D. Global analysis of cancer cell responses to USP9X inhibition. The EMBO Journal. 2026;45(9):10.1038/s44318-026-00742-y
Mansouri M, De Paoli A, Giannangelo C, Chowdury M, Ngo A, Shackleford DM, Webb CT, Lowes KN, Creek DJ, Charman SA, De Koning-Ward TF, McGowan S, Scammells PJ. Correction to “Novel Scaffold Unlocks Potent Cross-Peptidase and Cross-Species Inhibitors as Promising Antimalarial Agents”. Journal of Medicinal Chemistry. 2026;69(7):10.1021/acs.jmedchem.6c00778
Mansouri M, De Paoli A, Giannangelo C, Chowdury M, Ngo A, Shackleford DM, Webb CT, Lowes KN, Creek DJ, Charman SA, De F. Koning-Ward T, McGowan S, Scammells PJ. Novel Scaffold Unlocks Potent Cross-Peptidase and Cross-Species Inhibitors as Promising Antimalarial Agents. Journal of Medicinal Chemistry. 2026;69(2):10.1021/acs.jmedchem.5c02743
Favuzza P, Palandri J, de Lera Ruiz M, Bailey W, Boyce CW, Danziger A, Fawaz MV, Kelly M, Murgolo N, Robbins JA, Vavrek M, Zhao L, Lei Z, Guo Z, Reaksudsan K, Steel RWJ, Hodder AN, Ngo A, Dziekan JM, Thompson JK, Triglia T, Birkinshaw RW, Penington JS, Scally SW, Dans MG, Coyle R, Sevilleno N, Orban A, Feufack-Donfack LB, Popovici J, Lee MCS, Papenfuss A, Lowes KN, Sleebs BE, McCarthy JS, McCauley JA, Boddey JA, Olsen DB, Cowman AF. MK-7602: a potent multi-stage dual-targeting antimalarial. EBioMedicine. 2026;123:10.1016/j.ebiom.2025.106061
Wu X, Devine SM, Go M, Nguyen JV, Lu BGC, Loi K, Kuchel NW, Lowes KN, Mitchell JP, Lessene G, Komander D, Call ME, Call MJ. Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. PLOS Pathogens. 2025;21(9):10.1371/journal.ppat.1013468
M. Bader S, Calleja DJ, Devine SM, Kuchel NW, Lu BGC, Wu X, Birkinshaw RW, Bhandari R, Loi K, Volpe R, Khakham Y, Au AE, Blackmore TR, Mackiewicz L, Dayton M, Schaefer J, Scherer L, Stock AT, Cooney JP, Schoffer K, Maluenda A, Kleeman EA, Davidson KC, Allison CC, Ebert G, Chen G, Katneni K, Klemm TA, Nachbur U, Georgy SR, Czabotar PE, Hannan AJ, Putoczki TL, Tanzer M, Pellegrini M, Lechtenberg BC, Charman SA, Call MJ, Mitchell JP, Lowes KN, Lessene G, Doerflinger M, Komander D. A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. Nature Communications. 2025;16(1):10.1038/s41467-025-57905-4
Li K, Yap YQ, Moujalled DM, Sumardy F, Khakham Y, Georgiou A, Jahja M, Lew TE, De Silva M, Luo M-X, Gong J-N, Yuan Z, Birkinshaw RW, Czabotar PE, Lowes K, Huang DCS, Kile BT, Wei AH, Dewson G, van Delft MF, Lessene G. Differential regulation of BAX and BAK apoptotic activity revealed by small molecules. Science Advances. 2025;11(10):10.1126/sciadv.adr8146
Wu X, Go M, Nguyen JV, Kuchel NW, Lu BGC, Zeglinski K, Lowes KN, Calleja DJ, Mitchell JP, Lessene G, Komander D, Call ME, Call MJ. Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape. Nature Communications. 2024;15(1):10.1038/s41467-024-50566-9
In E-J, Tan T, Mouradov D, Sakthianandeswaren A, Au A, Lowes K, Sieber O. Abstract C043: Discovery of new drug combinations for metastatic colorectal cancer. Molecular Cancer Therapeutics. 2023;22(12_Supplement):10.1158/1535-7163.targ-23-c043
